Mckesson (MCK) Stock
Major pharmaceutical distributor supplying medicines to hospitals and pharmacies. Here's the price, business snapshot, and what's worth knowing about Mckesson in July 2026.
McKesson Corporation (ticker: MCK) is one of the world’s largest pharmaceutical distributors and healthcare services providers, supplying medicines, medical products and technology solutions to pharmacies, hospitals and manufacturers. With a market capitalisation of about $97.93B, McKesson operates a scale-driven business that benefits from recurring, high-volume flows but typically operates on thin distribution margins. Key investor considerations include exposure to the US healthcare system, sensitivity to drug pricing and reimbursement changes, ongoing regulatory and litigation risk, and the company’s push into specialty drugs, automation and software services that can lift profitability over time. McKesson historically generates significant cash flow and has returned capital to shareholders, but inventory- and working-capital intensity can create earnings volatility. This summary is for general, educational purposes only and not personal financial advice; values can fall as well as rise and suitability depends on individual circumstances.
Why It’s Moving
McKesson faces modest downside pressure as margin concerns keep investors cautious
- Investors are focusing on McKesson’s thin profitability, which makes the stock more sensitive to even small signs of margin pressure in healthcare distribution.
- The latest analyst tone points to a modest downside gap versus current levels, reinforcing the view that much of the near-term optimism may already be priced in.
- No major company-specific earnings or fresh catalyst appeared in the last 7 days, so the move is being driven more by valuation and sector margin concerns than by a new headline.
McKesson faces modest downside pressure as margin concerns keep investors cautious
- Investors are focusing on McKesson’s thin profitability, which makes the stock more sensitive to even small signs of margin pressure in healthcare distribution.
- The latest analyst tone points to a modest downside gap versus current levels, reinforcing the view that much of the near-term optimism may already be priced in.
- No major company-specific earnings or fresh catalyst appeared in the last 7 days, so the move is being driven more by valuation and sector margin concerns than by a new headline.
When is the next earnings date for McKesson (MCK)?
The next earnings date for MCK is expected on August 5, 2026, after the market close. This report should cover Q1 fiscal 2027 for McKesson. The date is an estimate based on the company’s historical reporting pattern, as the company has not yet formally confirmed the release date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying McKesson's stock with a target price of $948.67, indicating strong growth potential.
Financial Health
McKesson demonstrates solid cash flow and revenue, indicating strong business operations and financial stability.
Dividend
McKesson's dividend yield of 0.43% is relatively low, indicating limited dividend income for investors. If you invested $1000 you would be paid $4.30 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring MCK
US Pharma Reshoring | CDMOs & Supply Chain Stocks
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
Published: 4 April 2026
Explore BasketPharma Manufacturing | What's Next After TrumpRx
GlaxoSmithKline and Amgen are the latest pharmaceutical giants to join the TrumpRx platform, offering direct-to-consumer medications at reduced prices while committing to massive U.S. manufacturing investments. This evolving landscape creates compelling investment opportunities in domestic drug production facilities, supply chain logistics, and digital health aggregators that help patients navigate new pricing structures.
Published: 14 March 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketDrug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published: 9 January 2026
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketPharma Onshoring: What's Next for US Drug Supply
Merck is investing $3 billion in a new Virginia plant, signaling a major push for domestic pharmaceutical production. This theme focuses on companies poised to benefit from the broader trend of onshoring the U.S. drug supply chain.
Published: 21 October 2025
Explore BasketPharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: 12 October 2025
Explore BasketDomestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: 26 September 2025
Explore BasketPharma Investment Basket Explained (Eli Lilly+)
Nigeria's growing population is increasingly seeking exposure to global health advancements, particularly from leading pharmaceutical innovators. This basket provides potential exposure to this trend through a collection of US and EU-listed pharmaceutical, biotechnology, and healthcare supply chain companies.
Published: 11 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Scale & Reach
McKesson’s size delivers stable volumes and negotiating power, though low distribution margins mean scale doesn’t remove commercial or regulatory risk.
Technology Shift
Investment in automation and software could improve efficiency and margins over time, but returns depend on successful execution and adoption.
Policy & Regulation
Changes in drug pricing, reimbursement or legal outcomes can materially affect performance, so monitor regulatory developments closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
